Compare Huntington Bancshares Incorporated (HBAN) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Moderna, Inc. — how do they compare? Huntington Bancshares Incorporated trades at $18.28 (market cap $36.83B), while Moderna, Inc. trades at $58.45 (market cap $23.67B). The key difference: Huntington Bancshares Incorporated is the larger of the two by market cap, and Huntington Bancshares Incorporated pays a 3.41% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| HBAN | MRNA | |
|---|---|---|
Market Cap | $36.83B | $23.67B |
Sector | Financials | Health |
52-Week High | $19.27 | $81.80 |
52-Week Low | $15.02 | $22.36 |
Dividend Yield | 3.41% | — |
Enterprise Value | — | $19.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $18.17, down 0.44% on the day, with a bullish technical signal supported by moving averages. The stock shows a P/E of 13.9 and a net income margin of 25.13%, with Q2 2026 earnings expected at $0.39 per share. Recent news highlights the upcoming earnings report on July 23, 2026, and positive developments from the company's Texas expansion.
The outlook for HBAN is positive, driven by earnings growth potential and analyst consensus of $20.25 price target. Key risks include integration challenges from acquisitions and competitive pressures in regional banking markets. The stock presents a value opportunity with solid fundamentals, though investors should monitor expense management and loan growth trends.
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
